Legend Biotech Corporation (LEGN)

業務介紹

傳奇生物科技公司是一家處於臨床階段的生物製藥公司,通過其子公司在美國、中國和國際上從事腫瘤學和其他適應症的新型細胞療法的發現和開發。其主要產品候選藥物LCAR-B38M是一種嵌合抗原受體,用於治療多發性骨髓瘤(MM),並與標準三聯療法相比,用於治療revlimid耐藥性多發性骨髓瘤。該公司還擁有一系列較早階段的自體產品候選藥物,正處於I期臨床試驗階段,用於治療胃癌和T細胞淋巴瘤。此外,該公司正在開發針對CD20/CD22/CD19的CAR-T產品候選藥物,用於治療非霍奇金淋巴瘤、彌漫性大B細胞淋巴瘤和急性淋巴細胞白血病。此外,該公司還有一些用於治療實體瘤和傳染病的早期臨床前和臨床開發的產品候選藥物。該公司與Janssen Biotech, Inc.有合作和許可協議,用於開發和商業化ciltacabtagene autoleucel。傳奇生物科技公司成立於2014年,總部位於新澤西州的薩默塞特。傳奇生物科技公司是基因科技生物科技公司的子公司。



Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

公司網址

https://www.legendbiotech.com